Combining cagrilintide with tirzepatide could theoretically produce 20-30% body weight loss by targeting three distinct pathways (GIP, GLP-1, and amylin), but the lack of clinical data means dosing protocols are speculative, side effect profiles unknown, and safety unclear
Third-Party Independent Analytical Testing Available Upon Request for Additional Transparency & Assurance
Those trials arent there with the long-acting amylins, but theres a lot of preclinical data that is very interesting with these amylins
Theoretical concerns exist with anticoagulants, blood pressure medications, and immunosuppressants
BPC-157 works systemically proximity to the spine for subQ injection is less important than consistent daily dosing
While boosting already-normal levels wont create super-oxygenated blood, preventing any dip below optimal can maintain consistent performance capacity throughout heavy training blocks